# Akido Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akido-labs

- Industry: Healthcare IT
- Headquarters: West Hollywood, US
- Website: www.akidolabs.com/
- Total disclosed funding: $84M
- Latest round: Series B (Mar 11, 2025)
- Investors on record: 5

## About

Akido Labs, based in the US, specializes in delivering healthcare solutions via its innovative API platform, enabling tailored insurance products that enhance patient access and management throughout various life stages.Founded in 2015, Akido Labs, Inc. operates from West Hollywood, US, focusing on healthcare technology. The company has undergone strategic pivots to refine its offerings. The founders, Jared Goodner, Prashant Samant, and Revanth Reddy, have prior entrepreneurial experience. The company's latest funding round, the Series B, raised USD 84.255 mn in March 2025, led by Oak HC/FT Partners with participation from other investors such as Comprehensive Blood & Cancer Center and Y Combinator. Akido Labs has completed a total of 3 deals, with a current valuation of USD 339.966 mn.Akido Labs offers a range of innovative healthcare solutions primarily through its flagship product, Scope AI, which specializes in providing tailored insurance products across multiple life stages including life insurance, disability insurance, mental health coverage, medical reimbursement, and accident insurance. This service addresses various customer needs and enhances overall health management. Scope AI leverages advanced artificial intelligence to optimize patient interactions, facilitating increased access to in-person care and tackling challenges like long wait times and high out-of-pocket expenses. The company primarily serves patients across the United States, engaging a diverse client base that includes individual consumers seeking personalized healthcare coverage and providers looking to enhance patient access to quality care.Akido Labs generates revenue through a structured model that includes direct-to-consumer transactions and partnerships with healthcare providers. The company's offerings, such as Scope AI and various insurance products, are sold on a subscription basis, allowing for flexible payment plans tailored to individual needs. While specific pricing details are not disclosed, the revenue model accommodates a range of budgets, ensuring accessibility for a broad audience. The integration of AI technology in patient visits enhances the consumer experience and positions the company competitively within the healthcare insurance market, fostering long-term relationships with both patients and providers.In March 2025, Akido Labs Inc. raised USD 84.25 mn in Series B funding, led by new investor Oak HC/FT Partners, with contributions from Greco and SNR, along with returning investors like Y Combinator and Future Communities Capital. This funding will be utilized to broaden the application of its platform, Scope AI, with plans to introduce new products and expand into additional markets. Specific geographic regions targeted for expansion are not detailed, but the company is poised to capitalize on this recent investment to enhance its product offerings and market reach.

## Funding rounds

- Series B, Mar 11, 2025, $84M — Y Combinator, Oak HC/FT, Comprehensive Blood & Cancer Center, Future Communities Capital, SNR
- Seed, Mar 20, 2015, $0.1M — Y Combinator

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series B
- Oak HC/FT (https://capitalatlas.ai/funds/oak-hc-ft) — Series B
- Comprehensive Blood & Cancer Center — Series B
- Future Communities Capital (https://capitalatlas.ai/funds/future-communities-capital) — Series B
- SNR (https://capitalatlas.ai/funds/snr) — Series B